Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder
Pharmacopsychiatry · 01.07.2024 · 57 (04) · 173-179
DOI: 10.1055/a-2290-6386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.07.2024. Verfasst von Vicent Llorca-Bofí und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Clozapine is the recommended treatment for managing treatment-resistant schizophrenia (TRS), and immunological mechanisms may be involved in its unique antipsychotic efficacy. This study investigated whether baseline immune abnormalities measured with blood cell count ratios can predict the clinical response after initiating treatment with clozapine in patients with clozapine naïve TRS.
Methods
A longitudinal design was developed, involving 32 patients diagnosed with treatment-resistant, clozapine-naïve schizophrenia-spectrum disorder. Patients were evaluated at baseline before clozapine starting and 8 weeks of follow-up. Psychopathological status and immune abnormalities (blood cell count ratios: neutrophil-lymphocyte ratio [NLR], monocyte-lymphocyte ratio [MLR], platelet-lymphocyte ratio [PLR] and basophil-lymphocyte ratio [BLR]) were evaluated in each visit.
Results
Baseline NLR (b=− 0.364; p=0.041) and MLR (b =− 0.400; p=0.023) predicted the change in positive symptoms over the 8-week period. Patients who exhibited a clinical response showed higher baseline NLR (2.38±0.96 vs. 1.75±0.83; p=0.040) and MLR (0.21±0.06 vs. 0.17±0.02; p=0.044) compared to non-responders. In the ROC analysis, the threshold points to distinguish between responders and non-responders were approximately 1.62 for NLR and 0.144 for MLR, yielding AUC values of 0.714 and 0.712, respectively. No statistically significant differences were observed in the blood cell count ratios from baseline to the 8-week follow-up.
Conclusion
Our study emphasizes the potential clinical significance of baseline NLR and MLR levels as predictors of initial clozapine treatment response in patients with TRS. Future studies with larger sample sizes and longer follow-up periods should replicate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Barcelona, Barcelona, Spain.
- Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- University of Coimbra, Coimbra, Portugal.
- Bipolar and Depressive Disorders Unit, Neurosciences Institute, Hospital Clínic Barcelona, Barcelona, Spain.
Zitieren
APA
Llorca-Bofí, V., Bioque, M., Madero, S., Mallorquí, A., Oliveira, C., Garriga, M., Parellada, E., & García-Rizo, C. (2024). Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder. Pharmacopsychiatry, 57(04), 173-179. https://doi.org/10.1055/a-2290-6386
Vancouver
Llorca-Bofí V, Bioque M, Madero S, Mallorquí A, Oliveira C, Garriga M, et al. Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder. Pharmacopsychiatry. 2024;57(04):173-179. doi:10.1055/a-2290-6386
BibTeX
@article{LlorcaBof2024,
author = {Llorca-Bofí, Vicent and Bioque, Miquel and Madero, Santiago and Mallorquí, Andrea and Oliveira, Cristina and Garriga, Marina and Parellada, Eduard and García-Rizo, Clemente},
title = {Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder},
journal = {Pharmacopsychiatry},
year = {2024},
volume = {57},
number = {04},
pages = {173--179},
doi = {10.1055/a-2290-6386}
}
EUVIMED